Claude Science

Anthropic's Claude Science, an app adapting AI for biopharma research labs, was unveiled to highlight AI's potential beyond public concerns. The article notes widespread fears of AI as a job-eliminating tool and nuclear threat, contrasting with Claude Science's focus on scientific advancement.

Anthropic, an AI company, has developed a drug research tool called Claude Science to accelerate scientific discovery and is launching its own preclinical drug programs for neglected diseases. The company aims to address diseases less profitable for pharmaceutical industries by leveraging its public-benefit status to balance profit with public good.

Anthropic's CEO Dario Amodei revised his timeline for AI's impact on biotech, acknowledging that current AI tools may not yet enable the rapid progress he previously predicted. He cited limitations in model capabilities, the need for researchers to adapt to new tools, and slow infrastructure/regulatory changes as barriers. Anthropic introduced a biotech-focused product called Claude Science during an event.

Anthropic is launching an AI research workbench called Claude Science that integrates over 60 databases and tools. The platform operates using existing Claude models without requiring specialized biology training.

AI company Anthropic announced it will begin developing drugs, marking a new venture into life sciences. The company launched its newest application, Claude Science, and emphasized gaining hands-on experience to solve scientific problems using its AI products.

Anthropic announced Claude Science, a new flagship product designed to support scientific research, particularly in computational biology and drug development. The product is now available to paid subscribers and will be used by Anthropic for its own research on rare diseases. The company positions it alongside Claude Code and Claude Cowork, emphasizing its commitment to AI-driven scientific advancements.